Scientists have developed a test that uses cells from a single donor’s blood to predict whether a new drug will cause a severe reaction in humans.
The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.
Cytokine storm reactions are a particular worry for new biological therapies, or “biologics”, which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don’t materialise in animal studies, so tests on human cells are essential.
However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.
Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.
Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor’s own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.
The new method is better as it only requires blood from one donor and doesn’t mix cells from different people, with the advantage of making a more reliable test.
Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: “As biological therapies become more mainstream, it’s more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We’ve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.
“Drug companies have the technical capacity to start using this test now, but we’re working on developing an off-the-shelf kit which will make it easy to use on a large scale.”
Dr Daniel Reed, the first author on the study, said: ”A further benefit of this new technology is that personalised therapies can be tested to see how safe and effective they will be for an individual.”
The Latest on: Personalised therapies
via Google News
The Latest on: Personalised therapies
- OurCrowd leads $8M Series B in Israeli personalized cancer therapy startupon January 20, 2021 at 8:36 pm
Israeli startup OncoHost leverages AI technologies to better understand oncology patients' unique response to treatment, in an effort to combat growing cases of resistance to ...
- Collaborations with global academia, hospitals & start-ups to propel deployment of CAR-T therapy in India: Dr Anandon January 20, 2021 at 6:30 pm
Collaborations with global academia, hospitals & start-ups to propel deployment of CAR-T therapy in India: Dr Anand: Nandita Vijay, Bengaluru Thursday, January 21, 2021, 08:00 Hrs ...
- High-Dose Y-90 Pushes the HCC Paradigm Toward Personalized, Multidisciplinary Careon January 20, 2021 at 6:03 am
Beau Toskich, MD, discusses the potential of TheraSphere as a therapy in hepatocellular carcinoma, the importance of utilizing a multidisciplinary approach among novel radiation oncology agents, and ...
- Phoenix Physical Therapy Completes Three Acquisitions In Q4 2020on January 19, 2021 at 8:56 am
PRNewswire/ -- Phoenix Physical Therapy (“Phoenix”) completed three acquisitions in the fourth quarter of 2020, further expanding its geographic reach in Alabama, Delaware, and Maryland and entering ...
- Advarra Announces New Gene Therapy Ready Site Networkon January 19, 2021 at 5:07 am
Advarra, the market leader in regulatory review solutions and clinical site technologies, announces the Gene Therapy Ready(TM) site network, a comprehensive collective of ...
- NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICEon January 18, 2021 at 11:17 pm
NHS patients are to be among the first in the world to be offered access to a cutting-edge cancer treatment after NICE recommended its use. From today NHS clinicians in England will be able to ...
- Personalized Brain Stimulation Eases Depression Symptomson January 18, 2021 at 9:25 am
A novel personalized neuromodulation approach that at least in one patient provided relief from symptoms of severe treatment-resistant depression within minutes.
- Personalized neuromodulation approach provides relief from severe depression symptomson January 18, 2021 at 9:00 am
Targeted neuromodulation tailored to individual patients' distinctive symptoms is an increasingly common way of correcting misfiring brain circuits in people with epilepsy or Parkinson's disease.
- Personalized Brain Stimulation Alleviates Severe Depression Symptomson January 18, 2021 at 8:02 am
Depression is among the most common psychiatric disorders, affecting as many as 264 million people worldwide and leading to hundreds of thousands of deaths per year. But as many as 30 percent of ...
- Strata Oncology Announces Personalized Recurrence Monitoring Trialon January 13, 2021 at 4:30 am
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced plans to ...
via Bing News